Ontuxizumab: USAN; Rec INN

A. Tobias, M. Agulnik*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Ontuxizumab (MORAb-004) is a humanized recombinant monoclonal antibody targeting endosialin (encoded by the CD248 gene, also known as TEM1). Endosialin, a C-type lectin-like cell surface receptor, is a glycoprotein expressed on the surface of cells involved in the development of tumor vasculature, such as tumor-associated pericytes, stromal fibroblasts, and a subset of malignant cells themselves. Moreover, endosialin is a highly overexpressed antigen in tumor microvasculature and presents a lower level of expression in normal adult cells; therefore, its selective expression makes it an attractive targeted antiangiogenic marker in tumors, especially of mesenchymal origin. In the preclinical setting, ontuxizumab treatment significantly reduces tumor growth, metastasis and blood vessel formation. Results from phase I clinical trials utilizing ontuxizumab, the first clinical stage agent to target endosialin, have demonstrated encouraging safety and tolerability data as well as preliminary evidence of efficacy. Results from a phase II study of the safety and efficacy of ontuxizumab used in combination with gemcitabine and docetaxel for the treatment of metastatic soft tissue sarcoma are currently being analyzed.

Original languageEnglish (US)
Pages (from-to)471-476
Number of pages6
JournalDrugs of the Future
Volume41
Issue number8
DOIs
StatePublished - Aug 2016

Keywords

  • Antiangiogenic
  • Endosialin
  • MORAb-004
  • Ontuxizumab
  • Soft tissue sarcoma
  • TEM-1

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Ontuxizumab: USAN; Rec INN'. Together they form a unique fingerprint.

Cite this